A phase II trial in patients with acute promyelocytic leukaemia (APML) to evaluate the effects of: all-trans retinoic acid (ATRA) combined with intensive idarubicin during induction and consolidation; subsequent intermittent all-trans retinoic acid; and molecular monitoring for evidence of minimal residual leukaemia and for evidence of incipient relapse, as measured by remission rate, relapse rate and overall survival. (APML03)
收藏DataCite Commons2023-06-08 更新2024-07-13 收录
下载链接：
https://www.allg.org.au/datasets/apml03/
下载链接
链接失效反馈官方服务：
资源简介：
HeSANDA 1.0.0
提供机构：
Australasian Leukaemia and Lymphoma Group (ALLG)
创建时间：
2023-06-08
